ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi - Integrase inhibitor - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-01-27 14:49:56 Integrase inhibitors Abacavir Cyclopropanes Purines Antiretroviral drug HIV/AIDS Lamivudine Reverse-transcriptase inhibitor ViiV Healthcare Biology Chemistry Organofluorides		ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 168,86 KB Share Document on Facebook

	EUROPEAN PHARMACOPOEIA 8.4 INDEX To aid users the index includes a reference to the supplement in which the latest version of a text can be found. For example : Abacavir sulfate.......................................... DocID: 1qtmO - View Document
	“ตัวอย่างหน้าอนุมัติวทิ ยานิพนธ์ภาษาอังกฤษ กลุ่มวิทยาศาสตร์สุขภาพ” Thesis entitled “Associ DocID: 1pXIU - View Document
	ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL DocID: 1fNy0 - View Document
	Antiviral Therapy 9:Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance Kai Wang, Ekachai Jenwitheesuk, Ram Samudrala and John E Mittler* Department of Microbiology, Unive DocID: 1fvTD - View Document
	MULTI-‐TARGET PREDICTION Willem Waegeman NGDATA Europe Belgium DocID: 1aQSO - View Document